RTI Surgical (RTIX) Reports In-Line Q2 EPS, Beats on Revenues; Lowers FY17 EPS Guidance Below Consensus, Reduces High-End of FY17 Revenues Below Consensus
Go back to RTI Surgical (RTIX) Reports In-Line Q2 EPS, Beats on Revenues; Lowers FY17 EPS Guidance Below Consensus, Reduces High-End of FY17 Revenues Below Consensus| RTI Biologics, Inc. (NASDAQ: RTIX) | Delayed: 3.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.14 | 52 Week High | $4.65 | |||
| Open | $41.01 | 52 Week Low | $2.50 | |||
| Day High | $3.14 | P/E | N/A | |||
| Day Low | $3.14 | EPS | $-0.34 | |||
| Volume | 1,559 | |||||
